Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Viatris signs agreements with Biocon on $815m stake sale
Viatris will sell all of its convertible preferred equity in Biocon Biologics. The deal value comprises $415m in newly issued Biocon equity shares and $400m in cash. The
Viatris will sell all of its convertible preferred equity in Biocon Biologics. The deal value comprises $415m in newly issued Biocon equity shares and $400m in cash. The
The initiative aims to enhance biotechnology research and innovation in the region. The new memorandum of understanding (MOU) was signed to mark the 15-year collaboration between the two
Denali’s lead investigational TransportVehicle-enabled enzyme replacement therapy is intended to treat mucopolysaccharidosis type II (Hunter syndrome, a rare genetic disorder affecting boys). The US Food and Drug Administration
In October 2025, the two companies signed the deal as part of their focus on bispecifics and ADCs. The agreement aims to expedite the worldwide development and commercialisation
The licensing agreement covers Thailand, Singapore, the Philippines and Indonesia, granting Rxilient rights to market APP13007, a patented medicine for treating inflammation and pain after ocular surgery. It
This applies to patients previously treated with a covalent Bruton tyrosine kinase (BTK) inhibitor. The approval broadens Jaypirca’s label to cover patients at an earlier stage of treatment
With this collaboration, drug developers get access to the technology, which is designed to increase yields and reduce the time required to reach clinical trials. The ATUM’s transposase-based
The partnership brings together Citizen Health’s AI-based patient insights and advocacy networks with the expertise of UCB in drug development to improve patient outcomes. Under this agreement, Citizen
The designation, which covers serious and life-threatening diseases affecting those under 18, may allow the company a paediatric priority review voucher for future regulatory submissions. SGT-212 is designed
This submission is the initial application for VIZZ under the exclusive licence and commercialisation agreement signed between LENZ Therapeutics and Lotus in May 2025, and includes South Korea